Table 1.
Ongoing KRAS directed clinical trials involving metastatic CRC.
| Clinical Trial | Drug | Target | Cancer Type | Estimated Enrollment (N) | NCT ID |
|---|---|---|---|---|---|
| Phase I | MRTX849 | KRAS G12C inhibitor | KRAS G12C mutant cancers | 565 | NCT03785249 |
| Phase 1 | KRAS TCR | Anti-KRAS G12D engineered T-cells |
KRAS G12D Mutated cancer |
70 | NCT03745326 |
| Phase 1 | KRAS TCR | Anti-KRAS G12 V engineered T-cells |
KRAS G12V Mutated cancer |
110 | NCT03190941 |
| Phase 1 | GDC-6036+/− Atezolizumab, Cetuximab, Bevacizumab, Erlotinib | KRAS G12C Mutation | Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation | 342 | NCT0444987 |
| Phase 1 | BBP-398 | SHP2 inhibitor | MAPK pathway or RTK driven advanced solid tumors | 60 | NCT04528836 |
| Phase 1b/2 | Onvansertib (PCM-075) + FOLFIRI + bevacizumab | PLK-1 inhibitor | Metastatic CRC with KRAS mutation | 44 | NCT03829410 |
| Phase 1b/2 | SX-682 +/−nivolumab | CXCR1/2 inhibitor | Metastatic CRC, RAS mutated | 53 | NCT04599140 |
| Phase 1 | JNJ-74699157 | KRAS G12 C | KRAS mutated advanced solid tumor | 10 | NCT0400630 |
| Phase 1 | mRNA-5671/V941 +/−pembrolizumab | KRAS vaccine | KRAS mutant CRC, NSCLC and PDAC | 100 | NCT03948763 |
| Phase 1 | D-1553 | KRAS G12C inhibitor | KRAS mutated CRC and NSCLC | 200 | NCT04585035 |